



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/718,506

11/20/2003

Mark Dinsmore

082251-0153

1247

48329 7590 11/05/2007  
FOLEY & LARDNER LLP  
111 HUNTINGTON AVENUE  
26TH FLOOR  
BOSTON, MA 02199-7610

EXAMINER

HO, ALLEN C

ART UNIT

PAPER NUMBER

2882

MAIL DATE

DELIVERY MODE

11/05/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<p align="center"><b>Office Action Summary</b></p>	<p>Application No.</p> <p align="center">10/718,506</p>	<p>Applicant(s)</p> <p align="center">DINSMORE ET AL.</p>	
	<p>Examiner</p> <p align="center">Allen C. Ho</p>	<p>Art Unit</p> <p align="center">2882</p>	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 01 August 2007.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-19 and 21 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-19 and 21 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 20 November 2003 is/are: a) ☐ accepted or b) ☒ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

## DETAILED ACTION

### *Drawings*

1. The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the thermionic cathode must be shown or the feature(s) canceled from the claim(s). Fig. 5 only shows a photocathode. No new matter should be entered.
2. The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the first cladding shell claimed in claim 7 must be shown or the feature(s) canceled from the claim(s). No new matter should be entered.
3. The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the second cladding shell claimed in claim 8 must be shown or the feature(s) canceled from the claim(s). No new matter should be entered.
4. The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the means for controlling claimed in claim 11 must be shown or the feature(s) canceled from the claim(s). No new matter should be entered.

Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet,

Art Unit: 2882

even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

### *Claim Objections*

5. The claims are in improper format. No strike-through/brackets in new claims. Claims added to the patent must follow the number of the highest numbered patent claim (37 CFR 1.173(e)), and must be underlined in their entirety (37 CFR 1.173(d)).

6. Claims 9-12 are objected to because of the following informalities:

- (1) Claim 9 recites the limitation "the outer wall of the optical fiber" in line 8. There is insufficient antecedent basis for this limitation in the claim.
- (2) Claim 9 recites the limitation "the exterior of the optical fiber" in 15. There is insufficient antecedent basis for this limitation in the claim.

Appropriate correction is required.

7. Claims 13 and 14 are objected to because of the following informalities:

Art Unit: 2882

- (1) Claim 13 recites the limitation "the outer surface of the optical fiber" in line 6. There is insufficient antecedent basis for this limitation in the claim.
- (2) Claim 13 recites the limitation "the outer wall" in line 8. There is insufficient antecedent basis for this limitation in the claim.
- (3) Line 14, "with in" should be replaced by --within--.
- (4) Claim 13 recites the limitation "the exterior of the optical fiber" in line 15. There is insufficient antecedent basis for this limitation in the claim.

Appropriate correction is required.

8. Claim 16 is objected to because of the following informalities:

Line 9, "the" before "distal end of said housing" should be replaced by --a--.

Appropriate correction is required.

### ***Claim Rejections - 35 USC § 112***

9. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

10. Claim 21 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

11. Claim 21 recites the limitation "said x-ray target" in line 12. There is insufficient antecedent basis for this limitation in the claim.

*Claim Rejections - 35 USC § 102*

12. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

13. The Lovoi reference is a U.S. patent or U.S. patent application publication of a pending or patented application that claims the rejected invention. An affidavit or declaration is inappropriate under 37 CFR 1.131(a) when the reference is claiming the same patentable invention, see MPEP § 2306. If the reference and this application are not commonly owned, the reference can only be overcome by establishing priority of invention through interference proceedings. See MPEP Chapter 2300 for information on initiating interference proceedings. If the reference and this application are commonly owned, the reference may be disqualified as prior art by an affidavit or declaration under 37 CFR 1.130. See MPEP § 718.

14. Claims 1-6, 9-19, and 21 are rejected under 35 U.S.C. 102(e) as being anticipated by Lovoi (U. S. Patent No. 6,319,188 B1).

With regard to claim 1, Lovoi disclosed a therapeutic radiation source that comprise: (A) a flexible catheter (12) extending along a probe axis between a proximal end and a distal end of the catheter, the flexible catheter comprising optical delivery means extending along the probe axis and having an originating end and a terminating end, and adapted to for transmitting optical radiation incident on the originating end to the terminating end; (B) an optical source (24),

Art Unit: 2882

including means for generating a beam of optical radiation directed to the originating end of the optical delivery means; (C) a radiation source (14) coupled to the terminating end of the optical delivery means, comprising a substantially rigid housing (48, 50, 52) enclosing an electron source (32) and a target (58), the housing defining a substantially evacuated interior region extending along a beam axis between the electron source at an input end (40) of the housing and a radiation transmissive window (48, 50, 52) at an output end (46) of the housing (column 4, lines 14-25), (a) wherein the electron source and the target are disposed along the beam axis and spaced apart from and opposite each other, (b) wherein the electron source is adapted to emit electrons in response to optical radiation transmitted to the terminating end, and comprises a thermionic emitter having an electron emissive surface (column 2, lines 44-47), and (c) wherein the target is responsive to incident electrons to emit therapeutic radiation whereby therapeutic radiation emitted therefrom is directed through the radiation transmissive window; and (D) means (18, 30, 36) for establishing an accelerating electric field extending between the electron source toward the target, the electric field acting to accelerate electrons emitted from the electron source toward the target, wherein the optical delivery means are adapted for directing a beam of optical radiation transmitted therethrough to impinge upon the surface of the thermionic emitter, and wherein the beam of transmitted optical radiation has a power level sufficient to heat at least a portion of the surface to an electron emitting temperature so as to cause thermionic emission of electron from the surface.

With regard to claim 2, Lovoi disclosed a therapeutic radiation source according to claim 1, wherein the optical source is a laser (column 3, lines 22-23).

With regard to claim 3, Lovoi disclosed a therapeutic radiation source according to claim 1, wherein the therapeutic radiation comprises x-rays (column 4, lines 46-53).

With regard to claim 4, Lovoi disclosed a therapeutic radiation source according to claim 1, wherein the optical delivery means comprises a fiber optical cable assembly having a fiber optical element (28) extending from the originating end to the terminating end.

With regard to claim 5, Lovoi disclosed a therapeutic radiation source according to claim 4, wherein the means for establishing an accelerating electric field comprises: a power supply, having a first terminal (30) and a second terminal (36), and a drive means (18) for establishing an output voltage between the first terminal and the second terminal, the power supply being electrically coupled to the radiation source by way of the first terminal and the second terminal.

With regard to claim 6, Lovoi disclosed a therapeutic radiation source according to claim 4, wherein the fiber optical cable assembly further comprises: (A) an electrical conductive cable (30), wherein the fiber optical element is concentrically disposed around the electrically conductive cable; and (B) an electrically conductive outer shell (36), concentrically disposed around the fiber optical element, the fiber optical element forming an optically transmissive core (28).

With regard to claim 9, Lovoi disclosed a vascular probe that comprise: a flexible optical fiber (28) having a bore through its length; a first electrical conductor (30) extending through the bore of the optical fiber; a second conductor (36) on the outer surface of the optical fiber; an essentially cylindrical tube (14) formed of electrically insulative and x-ray transmissive material secured on a distal end of the optical fiber (column 4, lines 14-25), the tube having a proximal end (40) secured in a sealed connection to the outer surface of the optical fiber, at a positioned



Art Unit: 2882

spaced back from the end of the optical fiber, and the tube having a distal end (46) and defining a vacuum chamber within the tube; a cathode (32) secured to the end of the optical fiber within the tube, the cathode being electrically connected to the first conductor in the bore of the fiber, the cathode comprising a thermionic cathode which is excitable by heat to emit electrons (column 2, lines 44-47); an anode (58) formed within the tube near its distal end, and an anode conductor (62) connecting the second conductor from the outer surface of the optical fiber to the anode, with an x-ray target (column 4, lines 46-53) in the path of electrons moving from the cathode to the anode; optical radiation means (24) at the proximal end of the optical fiber for delivering optical radiation through the optical fiber, of sufficient power to heat the cathode so as to emit electrons; and means (18) for selectively switching electrical power to the cathode and anode to establish a potential between the cathode and the anode.

With regard to claim 10, Lovoi disclosed a vascular probe according to claim 9, wherein the optical radiation means comprises a diode laser (column 3, lines 22-23).

With regard to claim 11, Lovoi disclosed a vascular probe according to claim 9, the vascular probe further includes means (18) for controlling the potential between the cathode and the anode to control the level of x-ray output from the tube.

With regard to claim 12, Lovoi disclosed a vascular probe according to claim 9, wherein the anode includes the x-ray target (column 4, lines 46-53).

With regard to claim 13, Lovoi disclosed a vascular probe that comprises: a flexible optical fiber (28); a first electrical conductor (30) embedded in and extending through the length of the optical fiber; a second conductor (36) on an outer surface of the optical fiber; an x-ray tube (14) formed of electrically insulative material on a distal end of the optical fiber, the tube having

Art Unit: 2882

a proximal end (40) in a sealed relationship with the outer surface of the optical fiber, and the tube having a distal end (46) and defining a vacuum chamber within the tube between the ends of the tube; a cathode (32) at the end of the optical fiber within the tube, the cathode being electrically connected to the first electrical conductor in the optical fiber, the cathode comprising a thermionic cathode which is excitable by heat to emit electrons (column 2, lines 44-47); an anode (58) formed within the tube near its distal end, and an anode conductor (62) connecting the second conductor from the outer surface of the optical fiber to the anode, with an x-ray target in the path of electrons moving to the anode; optical radiation means (24) at the proximal end of the optical fiber for delivering optical radiation through the optical fiber, of sufficient power to heat the cathode so as to emit electrons; and means (18) for selectively switching electrical power to the cathode and anode to establish a potential between the cathode and the anode.

With regard to claim 14, Lovoi disclosed a vascular probe according to claim 13, wherein the anode includes the x-ray target (column 4, lines 46-53).

With regard to claim 15, Lovoi disclosed a flexible probe that comprises: (A) a flexible optical fiber (28) adapted for transmitting optical radiation incident on a proximal end to distal end; (B) an optical source (24) for generating optical radiation directed to the proximal end of the optical fiber; (C) an x-ray tube (14) coupled to the distal end of the optical fiber, comprising: (a) a thermionic cathode (32), responsive to optical radiation transmitted to the distal end of the optical fiber and incident upon a surface of the cathode to generate electrons, and (b) an x-ray target (58) responsive to incident electrons emitted from the thermionic cathode to emit x-rays; and (D) means (18) for accelerating electrons emitted from the thermionic cathode toward the x-ray target; wherein optical radiation has a power level sufficient to heat at least a portion of the

Art Unit: 2882

surface to an electron emitting temperature so as to cause thermionic emission of electrons from the surface (column 2, lines 44-47).

With regard to claim 16, Lovoi disclosed a vascular probe that comprises: (A) an optical source (24) for generating optical radiation; (B) a flexible optical fiber (28) having a proximal end and a distal end, and adapted for transmitting optical radiation from the optical source from the proximal end of the fiber to the distal end of the fiber; (C) an x-ray tube (14) coupled to the distal end of the optical fiber, comprising a substantially rigid housing defining a substantially evacuated interior region extending between a proximal end (40) and a distal end (46) of the housing, the housing containing a thermionic cathode (32) and an x-ray target (58) between its proximal end and the distal end, the distal end of the housing comprising x-ray transmissive material (column 4, lines 14-25), (a) wherein the thermionic cathode is responsive to the optical radiation transmitted to the distal end of the optical fiber to emit electrons, and (b) wherein the x-ray target is responsive to incident electrons emitted from the thermionic cathode to emit x-rays; and (D) means (18) for accelerating electrons emitted from the thermionic cathode toward the x-ray target; wherein the optical fiber is adapted to direct a beam of optical radiation transmitted therethrough to impinge upon a surface of the thermionic cathode, and wherein the beam of transmitted optical radiation has a power level sufficient to heat at least a portion of the surface to an electron emitting temperature so as to cause thermionic emission of electrons from the surface (column 2, lines 44-47).

With regard to claim 17, Lovoi disclosed a brachytherapy apparatus that comprises: (A) a flexible probe (12) including an optical fiber (28) adapted for transmitting optical radiation incident on a proximal end to a distal end; (B) an optical source (24) for generating optical

Art Unit: 2882

radiation directed to the proximal end of the optical fiber; (C) an x-ray tube (14) coupled to the distal end of the flexible probe, comprising: (a) a thermionic cathode (32), responsive to optical radiation transmitted to the distal end of the optical fiber and incident upon a surface of the cathode to generate electrons, and (b) an x-ray target (58) responsive to incident electrons emitted from the thermionic cathode to emit a therapeutically effective amount of x-rays; and (D) means (18) for accelerating electrons emitted from the thermionic cathode toward the x-ray target; wherein the optical fiber is adapted to direct optical radiation transmitted therethrough onto a surface of the thermionic cathode, and wherein optical radiation has a power level sufficient to heat at least a portion of the surface to an electron emitting temperature so as to cause thermionic emission of electron from the surface (column 3, lines 57-65).

With regard to claim 18, Lovoi disclosed an x-ray treatment apparatus that comprises: (A) a flexible fiber optic assembly (12), including an optical fiber (28) adapted for transmitting optical radiation incident on a proximal end of the fiber to a distal end of the fiber; (B) an optical source (24) for generating optical radiation directed to the proximal end of the optical fiber; (C) a power supply (18) including a first terminal (30) and a second terminal (36), and means for establishing an output voltage between the first terminal and the second terminal; and (D) an x-ray target assembly (14) affixed to the distal end of the optical fiber and electrically coupled to the power supply by way of the first terminal and the second terminal, the x-ray target assembly including an x-ray target (58) having at least one x-ray emissive element for emitting x-ray radiation in a predetermined spectral range in response to the optical radiation transmitted to the distal end of the optical fiber, the x-ray target assembly further including an optically driven

Art Unit: 2882

thermionic emitter (32) adapted to generate electrons in response to the optical radiation transmitted through the optical fiber.

With regard to claim 19, Lovoi disclosed an x-ray treatment apparatus in accordance with claim 18, wherein the x-ray target assembly includes a substantially rigid housing defining a substantially evacuated interior region extending along a beam axis between the thermionic emitter at an input end (40) of the housing and an x-ray transmissive window at an output end (46) of the housing (column 4, lines 14-25), the housing having the input end affixed to the distal end of the optical fiber, wherein upon activation the power supply establishes an accelerating electric field between the x-ray emissive element and the thermionic emitter, the electric field acting to accelerate electrons emitted from the thermionic emitter toward the x-ray target, and wherein the x-ray target is responsive to incident accelerated free electrons to emit x-ray radiation.

With regard to claim 21, Lovoi disclosed a probe that comprises: a flexible optical fiber (28); an optical source (24) configured to generate optical radiation directed to a proximal end of the optical fiber; a tube (14) secured on a distal end of the optical fiber, the tube having a distal end (46) and a proximal end (40), the tube comprising x-ray transmissive material and defining a vacuum chamber within the tube (column 4, lines 14-25); a cathode (32) within the tube and secured to the distal end of the optical fiber, the cathode comprising a thermionic cathode which is excitable by heat to emit electrons (column 2, lines 44-47); and means (18) for selectively providing electric power to the cathode and the x-ray target to establish a potential between the cathode and the x-ray target.

***Claim Rejections - 35 USC § 103***

15. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

16. Claims 7 and 8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lovoi (U. S. Patent No. 6,319,188 B1) as applied to claim 6 above, and further in view of Oettinger *et al.* (U. S. Patent No. 5,428,658).

With regard to claims 7 and 8, Lovoi disclosed a therapeutic radiation source according to claim 6. However, Lovoi failed to disclose a fiber optical cable assembly that further comprises a first cladding shell and a second cladding shell, the first cladding shell and the second cladding shell having an index of refraction less than the index of refraction of the transmissive core.

Oettinger *et al.* disclosed a fiber optical cable assembly that comprises an optically transmissive core (250), a first cladding shell (260) concentrically disposed between an electrically conductive cable (208) and the optically transmissive core, and a second cladding shell (260) concentrically disposed between the optically transmissive core and an electrically conductive outer shell (204), wherein the first cladding shell and the second cladding shell having an index of refraction less than the index of refraction of the optically transmissive core (claims 26 and 27). Oettinger *et al.* taught that the first cladding shell and the second cladding shell refract a light beam that is incident on an interface back into the optically transmissive core to eliminate absorption and scattering of the light beam (column 24, line 61 - column 25, line 2).

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to provide a first cladding shell and a second cladding shell, since a person would be motivated to increase transmission efficiency by reducing absorption and scattering of optical radiation being transmitted.

### *Interference*

17. Applicant failed to provide sufficient information to identify the application or patent with which the applicant seeks an interference. See 37 CFR 41.202(a)(1) and MPEP § 2304.02(a).

18. Applicant failed to (1) identify all claims the applicant believes interfere, and/or (2) propose one or more counts, and/or (3) show how the claims correspond to one or more counts. See 37 CFR 41.202(a)(2) and MPEP § 2304.02(b).

19. Applicant failed to provide a claim chart comparing at least one claim of each party corresponding to the count. See 37 CFR 41.202(a)(3) and MPEP § 2304.02(c).

20. Applicant failed to provide a detailed explanation as to why applicant will prevail on priority. See 37 CFR 41.202(a)(4), (a)(6), (d) and MPEP § 2304.02(c).

21. Claims 18, 19, and 21 have been amended in a communication filed on 23 August 2005 to provoke an interference. Applicant failed to provide a claim chart showing the written description for each claim in the applicant's specification. See 37 CFR 41.202(a)(5) and MPEP § 2304.02(d).

Applicant's response to this office action must correct the above mentioned deficiencies.

***Response to Amendment***

22. Applicants' arguments filed 01 August 2007 with respect to claims 15-17 have been fully considered. The objection of claims 15-17 has been withdrawn.

23. Applicants' arguments filed 01 August 2007 with respect to claim 16 have been fully considered. The rejection of claim 16 under 35 U.S.C. 112, second paragraph, has been withdrawn.

***Response to Arguments***

24. Applicant's arguments filed 01 August 2007 have been fully considered but they are not persuasive.

With respect to the objections of the drawings, the applicants argue that a drawing is not essential if the specification provides an adequate disclosure of the invention. This response fails to comply with 37 CFR 1.83(a), which requires the drawings in a nonprovisional application to show every feature of the invention specified in the claims. Therefore, the objections are being maintained.

With respect to the objections of claims 9-14, the applicants argue that claims 9-14 have appropriate antecedent basis. The examiner respectfully disagrees. The applicants failed to point out where the antecedent basis is. Therefore, the objections are being maintained.

With respect to the rejection of claim 21 under 35 U.S.C. 112, second paragraph, for lack of sufficient antecedent basis of "said x-ray target", the applicants argue that support can be found throughout the original specification. This argument is not persuasive as "said x-ray target" lacks antecedent basis in claim 21. Therefore, the rejection is being maintained.



With respect to the rejection of claims 1-6, 9-19, and 21 under 35 U.S.C. 102(e) as being anticipated by Lovoi (U. S. Patent No. 6,319,188 B1), the applicants argue that an affidavit under 37 C.F.R. 1.131 is appropriate for claims that are not copied from U. S. Patent No. 6,319,188 B1. The examiner respectfully disagrees. MPEP § 715.05 states "A 37 CFR 1.131 affidavit is ineffective to overcome a United States patent or patent application publication, not only where there is a verbatim correspondence between claims of the application and of the patent, but also where there is no patentable distinction between the respective claims." Furthermore, MPEP § 715.05 states "An applicant who is claiming an invention which is identical to, or obvious in view of, the invention as claimed in a domestic patent or patent application publication cannot employ an affidavit under 37 CFR 1.131 as a means for avoiding an interference with the reference." Applicants' only option, if any, must be by way of 37 C.F.R. 41.202 instead of 37 CFR 1.131.

In this case, the claims are subject to a rejection under 35 U.S.C. 102(e). Until applicants provide the necessary showing under 37 CFR 41.202, the examination is not complete pursuant to 37 CFR 41.102. To overcome the rejection, the applicants must provide a detailed explanation as to why applicants will prevail on priority. See 37 CFR 41.202(a)(4), (a)(6), (d) and MPEP § 2304.02(c). Since the applicants have not provided a showing of priority, the rejection is being maintained.

***Conclusion***

25. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Allen C. Ho whose telephone number is (571) 272-2491. The examiner can normally be reached on Monday - Friday from 9:00 am - 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Edward J. Glick can be reached on (571) 272-2490. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 2882

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Allen C. Ho/  
Primary Examiner  
Art Unit 2882

29 October 2007